Payment & Shipping Terms:
|CasNo:||152459-95-5||Appearance:||White Crystalline Powder|
|Molecular Formula:||C30H35N7O4S||PackAge:||According To The Clients Requirement|
|Stock:||Mass Stock||Name:||Imatinib Mesylate|
Active Pharmaceutical Ingredients CAS 220127-57-1 Imatinib Mesylate White powder
Imatinib Mesylate Basic information
|Product Name||Imatinib Mesylate|
|Alias||Imatinib Methanesulfonate, STI-571, CGP-57148B, Glivec|
|Appearance||white Crystalline Powder|
|Packing Methods||foil bag or as your mind|
|Delivery time||within 18 hours after payment confirmed|
|Payment||T/T, Western Union,Money Gram , Bitcoin|
|Usage||Imatinib Mesylate is mainy used for anti tumor
Imatinib Mesylate is a tyrosine kinase inhibitor
Imatinib Mesylate Product Description
Imatinib mesylate is a tyrosine kinase inhibitor IC50 value of 100 nM, 100 nM, 600 nM for v-Abl, c-kit, PDGFR, respectively.
Imatinib Mesylate is a specific tyrosine kinase (abl, c-kit, and PDGFR) inhibitor and is reported to sensitize cells to radio- or chemo-therapy. When tested with Y-79 and WERI-RB-1 Rb cell lines, imatinib mesylate treatment decreased the cell proliferation and invasion with the concentration of 10 μM . In osteoblast cells, administration of imatinib mesylate decreased osteoclast development via stimulating differentiation, inhibiting proliferation and survival .
In dog model with mast cell tumor, administration of imatinib mesylate at a dose of 10 mg/kg daily for 1-9 weeks reduced tumor growth via inhibiting tyrosine kinase .
Imatinib Mesylate Applications
Cells were stimulated with allogeneic mature DCs or PHA in the presence of imatinib mesylate. The drug inhibited T-cell proliferation as a function of concentration. The effects were significant at 0.5 μM imatinib mesylate for the cells stimulated by DCs and at 1.0 μM imatinib mesylate for the cells stimulated with PHA. The IC50 values for imatinib mesylate-inhibited T-cell proliferation stimulated by DCs and PHA were 3.9 μM and 2.9 μM, respectively..
A tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL)
Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib
Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.
echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis
Starting dose: in patients with chronic myelogenous leukemia radically increasing stage and accelerating stage, imatinib mesylate in the recommended dose of 600 mg/day; Chronic-phase of interferon treatment failure, and cannot be removed surgically or metastatic malignant gastrointestinal stromal tumors (GIST) patients, and the recommended dose of 400 mg/day, both for once-daily oral, appropriate medication when eating, and drinking a glass of water, as long as effective, should be continued.